Resources from the same session
1360MO - Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study
Presenter: Karim Fizazi
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA64 - Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data
Presenter: Sarah Burdett
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1360MO and LBA64
Presenter: Nicolas Mottet
Session: Mini Oral session: GU tumours, prostate
Resources:
Slides
Webcast
1359MO - Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE
Presenter: Áine Haran
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1361MO - 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial
Presenter: Gwenaëlle Gravis Mescam
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1359MO and 1361MO
Presenter: Boris Hadaschik
Session: Mini Oral session: GU tumours, prostate
Resources:
Slides
Webcast
LBA65 - SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial
Presenter: Christian Rothermundt
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1362MO - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
Presenter: Evan Yu
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1363MO - Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
Presenter: Stephane Oudard
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1364MO - Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients
Presenter: Karim Fizazi
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast